In September and October this year, the EU-Japan Biotech & Pharma Partnering Conference will once again bring together biotech and pharma companies from Europe and Japan, both online and on-site in Osaka, Japan. The partnering event, jointly organised by the Osaka Prefectural Government and the EU-Japan Centre with the support of various clusters and other partners, will focus on the Kansai region around Osaka, one of Japan's two bio-communities of global reach along with the capital region.
Dates:
Registration Deadline: 30 September 2024
The online meeting sessions in September will enable first contacts and help European companies unable to travel to Japan, to connect with potential Japanese partners. For companies traveling to Japan planning to attend the BioJapan trade fair (9-11 October in Yokohama), the Centre’s event in Osaka is a perfect opportunity to capitalize on your mission adding another networking event to your agenda. The main partnering event, including a luncheon and evening reception, will be held on Monday, 7 October. A site visit to a centre for future medical care in Osaka is planned for 8 October. This completes a week of opportunities in Japan that should be on the schedule of anyone targeting the Japanese pharma and therapeutics market.
Why attend?
Who should attend?
European and Japanese pharmaceutical and biotech companies, drug discovery ventures, drug discovery service providers and innovators: in digital medicine and therapeutics.
The organisers reserve the right to reject applicants deemed ineligible or outside the target sector.
Do not miss this unique opportunity to foster collaboration, exchange ideas, and drive innovation in the biotech and pharma sectors!
Published: June 2024
The EU-Japan Centre currently produces 5 newsletters :
Joint venture established in 1987 by the European Commission (DG GROW) and the Japanese Government (METI) for promoting all forms of industrial, trade and investment cooperation between the EU and Japan.
The EU-Japan Centre’s activities are subject to the allocation of a Grant Agreement by the European Commission for 2024-2026